These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35615090)

  • 1. Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.
    Lee CH; Huang YC; Li SS; Hsu YT; Chen YP; Chen TY
    Front Med (Lausanne); 2022; 9():893273. PubMed ID: 35615090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada.
    Wynick C; Britto J; Sawler D; Parker A; Karkhaneh M; Goodyear MD; Sun HL
    Thromb Res; 2020 Dec; 196():335-339. PubMed ID: 32977133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
    Bendapudi PK; Hurwitz S; Fry A; Marques MB; Waldo SW; Li A; Sun L; Upadhyay V; Hamdan A; Brunner AM; Gansner JM; Viswanathan S; Kaufman RM; Uhl L; Stowell CP; Dzik WH; Makar RS
    Lancet Haematol; 2017 Apr; 4(4):e157-e164. PubMed ID: 28259520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of PLASMIC score in a cohort of patients with suspected thrombotic microangiopathy in an academic medical centre.
    Tufano A; Polimeno M; Matani B; Cardillo G; Capasso F; Mormile R; Paladino F; Di Minno G
    Blood Transfus; 2023 Jul; 21(4):345-349. PubMed ID: 35969133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country.
    Oliveira DS; Lima TG; Benevides FLN; Barbosa SAT; Oliveira MA; Boris NP; Silva HF
    Hematol Transfus Cell Ther; 2019; 41(2):119-124. PubMed ID: 31079658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
    Li A; Khalighi PR; Wu Q; Garcia DA
    J Thromb Haemost; 2018 Jan; 16(1):164-169. PubMed ID: 29064619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silent Thrombotic Thrombocytopenic Purpura: PLASMIC, Lessons Learned, and Current Management Overview.
    Pisklakova A; Barbir J; Sambataro JP; Almanzar C; Manji F
    Cureus; 2021 Mar; 13(3):e13803. PubMed ID: 33842174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Validation of Three Scoring Systems for the Prediction of Thrombotic Microangiopathy Due to Severe ADAMTS13 Deficiency and the Response to Therapeutic Plasma Exchange: First Study in Korea.
    Park SH; Kim HK; Jeong J; Lee SH; Lee YJ; Kim YJ; Jo JC; Lim JH
    Ann Lab Med; 2023 Sep; 43(5):485-492. PubMed ID: 37080750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
    Tiscia GL; Ostuni A; Cascavilla N; Cappucci F; Scalzulli P; Battista C; Abrescia A; Aucella F; Buquicchio C; Brigante M; D'Andrea G; Di Paolo B; Giordano G; Infante B; Piano S; Ranieri P; Tullo L; Grandone E
    J Thromb Thrombolysis; 2018 Aug; 46(2):174-179. PubMed ID: 29737462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
    Bentley MJ; Wilson AR; Rodgers GM
    Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified PLASMIC score including the lactate dehydrogenase/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score.
    Zhao N; Zhou L; Hu X; Sun G; Chen C; Fan X; Zhou S; Tao X; Liu H; Zheng C
    J Clin Apher; 2020 Apr; 35(2):79-85. PubMed ID: 31724781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura.
    Reeves HM; Maitta RW
    Thromb Res; 2022 Jul; 215():30-36. PubMed ID: 35617796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.
    Tang N; Wang X; Li D; Sun Z
    Thromb Res; 2018 Dec; 172():9-13. PubMed ID: 30340093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.
    Kim CH; Simmons SC; Williams LA; Staley EM; Zheng XL; Pham HP
    Transfusion; 2017 Nov; 57(11):2609-2618. PubMed ID: 28646526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
    Mariotte E; Azoulay E; Galicier L; Rondeau E; Zouiti F; Boisseau P; Poullin P; de Maistre E; Provôt F; Delmas Y; Perez P; Benhamou Y; Stepanian A; Coppo P; Veyradier A;
    Lancet Haematol; 2016 May; 3(5):e237-45. PubMed ID: 27132698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the PLASMIC score at a University Medical Center.
    Jajosky R; Floyd M; Thompson T; Shikle J
    Transfus Apher Sci; 2017 Aug; 56(4):591-594. PubMed ID: 28764998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.
    Upadhyay VA; Geisler BP; Sun L; Uhl L; Kaufman RM; Stowell C; Makar RS; Bendapudi PK
    Br J Haematol; 2019 Aug; 186(3):490-498. PubMed ID: 31131442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A validation and modification of PLASMIC score by adjusting the criteria of mean corpuscular volume and international normalized ratio.
    Lee JA; Lin MH; Kang CM; Chuang MK; Fung CKB; Lo SC
    J Clin Apher; 2023 Oct; 38(5):582-589. PubMed ID: 37325919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of PLASMIC score: an academic medical center case series (2012-present).
    Moosavi H; Ma Y; Miller MJ; Duncan A
    Transfusion; 2020 Jul; 60(7):1536-1543. PubMed ID: 32588918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.